Calzetti S - Search Results

1

A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy.

Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, Calzetti S. Smargiassi A, et al. Among authors: calzetti s. Neurotoxicology. 1998 Aug-Oct;19(4-5):709-12. Neurotoxicology. 1998. PMID: 9745932

2

Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility.

Negrotti A, Calzetti S, Sasso E. Negrotti A, et al. Among authors: calzetti s. Neurotoxicology. 1992 Spring;13(1):261-4. Neurotoxicology. 1992. PMID: 1508427

3

Absence of co-morbidity of Parkinson disease and restless legs syndrome: a case-control study in patients attending a movement disorders clinic.

Calzetti S, Negrotti A, Bonavina G, Angelini M, Marchesi E. Calzetti S, et al. Neurol Sci. 2009 Apr;30(2):119-22. doi: 10.1007/s10072-009-0037-7. Epub 2009 Mar 10. Neurol Sci. 2009. PMID: 19277834

4

A case-control study of Parkinson's disease and tobacco use: gene-tobacco interactions.

De Palma G, Dick FD, Calzetti S, Scott NW, Prescott GJ, Osborne A, Haites N, Mozzoni P, Negrotti A, Scaglioni A, Mutti A; Geoparkinson Study Group. De Palma G, et al. Among authors: calzetti s. Mov Disord. 2010 May 15;25(7):912-9. doi: 10.1002/mds.22980. Mov Disord. 2010. PMID: 20461808

5

L-deprenyl as an adjunct to low-dose bromocriptine in early Parkinson's disease: a short-term, double-blind, and prospective follow-up study.

Calzetti S, Negrotti A, Cassio A. Calzetti S, et al. Clin Neuropharmacol. 1995 Jun;18(3):250-7. doi: 10.1097/00002826-199506000-00005. Clin Neuropharmacol. 1995. PMID: 8635183 Clinical Trial.

6

A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism.

Negrotti A, Calzetti S. Negrotti A, et al. Among authors: calzetti s. Mov Disord. 1997 Jan;12(1):107-10. doi: 10.1002/mds.870120119. Mov Disord. 1997. PMID: 8990063

7

Case-control study of interactions between genetic and environmental factors in Parkinson's disease.

De Palma G, Mozzoni P, Mutti A, Calzetti S, Negrotti A. De Palma G, et al. Among authors: calzetti s. Lancet. 1998 Dec 19-26;352(9145):1986-7. doi: 10.1016/s0140-6736(05)61332-3. Lancet. 1998. PMID: 9872254 No abstract available.

8

Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.

Negrotti A, Bizzarri G, Calzetti S. Negrotti A, et al. Among authors: calzetti s. J Neural Transm (Vienna). 2001;108(2):215-9. doi: 10.1007/s007020170089. J Neural Transm (Vienna). 2001. PMID: 11314774 Clinical Trial.

9

A study of the prevalence of restless legs syndrome in previously untreated Parkinson's disease patients: absence of co-morbid association.

Angelini M, Negrotti A, Marchesi E, Bonavina G, Calzetti S. Angelini M, et al. Among authors: calzetti s. J Neurol Sci. 2011 Nov 15;310(1-2):286-8. doi: 10.1016/j.jns.2011.08.012. Epub 2011 Sep 1. J Neurol Sci. 2011. PMID: 21889169

10

A long-term prospective follow-up study of incident RLS in the course of chronic DAergic therapy in newly diagnosed untreated patients with Parkinson's disease.

Calzetti S, Angelini M, Negrotti A, Marchesi E, Goldoni M. Calzetti S, et al. J Neural Transm (Vienna). 2014 May;121(5):499-506. doi: 10.1007/s00702-013-1132-8. Epub 2013 Dec 20. J Neural Transm (Vienna). 2014. PMID: 24357050

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters